UNC0638 inhibits SARS-CoV-2 entry by blocking cathepsin L maturation

  • J Virol. 2025 Jul 22;99(7):e0074125. doi: 10.1128/jvi.00741-25.
Yongjun Chen  #  1  2 Yujin Shi  #  1  2 Xiaoyan Zuo  1  2 Xiaojing Dong  1  2 Xia Xiao  1  2 Lan Chen  1  2 Zichun Xiang  1  2 Lili Ren  1  2 Zhuo Zhou  3 Wensheng Wei  4 Xiaobo Lei  1  2 Jianwei Wang  1
Affiliations
  • 1. NHC Key Laboratory of System Biology of Pathogens, Christophe Mérieux Laboratory National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • 2. Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College) Ministry of Education, Beijing, China.
  • 3. State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
  • 4. Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing, China.
  • # Contributed equally.
Abstract

Since the outbreak of SARS-CoV-2, viral mutations have posed significant challenges in identifying therapeutic targets and developing broad-spectrum Antiviral drugs. Post-translational modifications of genes involved in interferon production and signaling pathways play a crucial role in regulating interferon responses. In this study, we employed CRISPR-Cas9 screening based on adenine base editors to investigate functional Amino acids in 1,278 innate immune-related genes. This approach, which converts A-T base pairs into G-C base pairs to probe the functional importance of specific Amino acids, allowed us to identify 17 vital factors involved in SARS-CoV-2 Infection. Among the candidate genes, genetic knockdown of EHMT2 exhibited the strongest Antiviral effect. Further analysis revealed that UNC0638, a selective inhibitor of EHMT2, significantly reduced the endosomal entry of SARS-CoV-2 in pseudovirus assays. The observed inhibitory effect was consistently observed across multiple SARS-CoV-2 variants, including Alpha, Beta, Delta, and Omicron. Mechanistically, UNC0638 reduced mature Cathepsin L (CTSL) levels, impairing the proteolytic cleavage of SARS-CoV-2 spike protein and subsequent membrane fusion, a critical step for viral entry. Our findings uncover EHMT2 as a host dependency factor and reveal the Antiviral mechanism of EHMT2 inhibitors through CTSL maturation blockade. These results advance the understanding of host factors in SARS-CoV-2 Infection and provide a strategic framework for developing host-targeted Antiviral therapies.IMPORTANCEIn this study, we demonstrated that knockdown or knockout of EHMT2 inhibited SARS-CoV-2 Infection, and inhibitors of EHMT2, including UNC0638, UNC0642, and BIX01294 showed similar restrictive effects. Mechanistically, the EHMT2 inhibitor UNC0638 restricts spike-mediated cell entry by inhibiting the maturation of CTSL, a critical protease required for SARS-CoV-2 entry via the endosomal pathway. Importantly, CTSL is not only essential for SARS-CoV-2 but also plays a key role in the entry of Other coronaviruses that utilize similar pathways. Therefore, EHMT2 inhibitors could have broader applications as pan-coronavirus therapeutic agents.

Keywords
EHMT2; SARS-CoV-2; UNC0638; cathepsin L; viral entry.
Products
Inhibitors & Agonists
Other Products